C-XLI9FibroBiologics
fibroblast cell therapy, regenerative medicine, immune modulation
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XLI9
C-XLI9C-XLI9fibroblast cell therapy, regenerative medicine, immune modulation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Many autoimmune treatments work by turning down the immune system. That can reduce symptoms. But it can also weaken the body’s natural defenses. In this conversation, our leadership team explains why FibroBiologics is studying a different approach, one focused on restoring balance instead of shutting the immune system down. It’s a new way of thinking about chronic disease. NASDAQ: FBLG #FibroBiologics #ImmuneHealth #MedicalInnovation #Biotech #futureofmedicine Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy
In the latest Better Biopharma podcast from BioProcess Online, host Tyler Menichiello is joined by FibroBiologics CEO and Founder Pete O’Heeron and CSO Hamid Khoja, Ph.D., to discuss FibroBiologics’ mission to make fibroblasts a more prominent platform in cell therapy. In this clip, Pete’s framing is straightforward: fibroblasts are the most common cell in the human body and outnumber stem cells 5,000:1, with practical advantages they test for, including potency, ease of harvesting, and ease of growth.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and Founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D. They discuss the powerful but often overlooked fibroblast, a type of connective-tissue cell that has tremendous therapeutic potential, according to O’Heeron and Khoja. They explain the company’s mission to realize this therapeutic potential and make fibroblasts a mainstay in the cell therapy space, rivaling the prominence of stem cells. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions -- Subscribe to the podcast! Apple - https://podcasts.apple.com/us/podcast/better-biopharma/id1826998821 Spotify - https://open.spotify.com/show/3dvQdILf6OLtWwhpMfxqYA YouTube - https://www.youtube.com/playlist?list=PLFX
Hamid Khoja, Ph.D., Chief Scientific Officer FibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. Our proprietary fibroblast platform serves as the foundation for developing biologic cures and treatments for chronic diseases, including wound healing multiple sclerosis, degenerative disc disease, psoriasis, cancer, and anti-aging extension of life applications such as thymic involution reversal. Currently, FibroBiologics holds 240+ U.S. and International issued/pending patents across a variety of clinical pathways, including wound healing, multiple sclerosis, cartilage repair, psoriasis, degenerative disc, cancer, and extension of life programs. www.FibroBiologics
This is a prospective, multicentre, randomized clinical trial evaluating the safety, tolerability, and efficacy of up to 12 weeks treatment with SoC + low- or high-dose CYWC628 in treating DFU, compared to SoC only.
In our ongoing work to harness fibroblasts for therapeutic applications, Dr. Hamid Khoja, Chief Scientific Officer of FibroBiologics, explains the potential of fibroblast therapies to improve both the speed and quality of wound healing.
Dr. Hamid Khoja, CSO of FibroBiologics, shares how fibroblasts could support tissue repair for conditions like multiple sclerosis (MS) and degenerative disc disease. Research in animal models shows promising results in remyelination and spinal disc repair when inflammation is controlled.
FibroBiologics highlights a preliminary proof of concept for a fibroblast-based treatment aimed at diabetes. This method, leveraging pancreatic beta cell spheroids for insulin secretion, opens potential new avenues for managing insulin-dependent diabetes. Dr. Hamid Khoja, our Chief Scientific Officer, highlights this important step toward developing a minimally invasive therapy for type 1 diabetes.
Research led by Dr. Hamid Khoja at FibroBiologics is potentially paving the way for new treatment avenues in multiple sclerosis (MS) using fibroblast cell therapy. Our team's work focuses on the immune modulation capabilities of fibroblasts, which play a role for bringing the dysregulated immune system of MS patients back to homeostasis.
Dr. Hamid Khoja, Chief Scientific Officer of FibroBiologics, explores potential innovative fibroblast-mediated therapies as non-surgical treatments for degenerative disc disease. Watch Dr. Hamid discuss FibroBiologics’ novel approach that could leverage the unique properties of fibroblasts to not only repair but also possibly replace damaged cartilage tissue in the spine. For more about our science, please visit https://fibrobiologics.com/technology/
#youtubeshorts from @ProgressPotentialPossibilities Pete O’Heeron - CEO, FibroBiologics - Developing & Commercializing Fibroblast Cell-Based Therapies https://www.youtube.com/watch?v=oOQOnUbaRVM #PeteOHeeron #FibroBiologics #Fibroblast #CellBasedTherapies #CellTherapy #RegenerativeMedicine #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
Dr. Hamid Khoja, Chief Scientific Officer of FibroBiologics (Nasdaq: FBLG) shares insights into our potentially groundbreaking work in wound healing by utilizing fibroblast-mediated therapies. By employing spheroids of specific fibroblast subtypes, Dr. Khoja and his team aim to accelerate the healing process and significantly reduce the recurrence rates of diabetic foot ulcers (DFU), which pose a significant challenge in patient care. For more about our science, please visit https://bit.ly/3xDByyw
Watch Hamid Khoja, Ph.D., FibroBiologics’ Chief Scientific Officer talk about his Nasdaq Bell Ringing Ceremony experience and how it helps to underscore our commitment towards research and development efforts against diseases.
Are stem-cell treatments the future of self-therapy and regenerative medicine? Or is there something better? In the latest episode of HealthBiz Briefs, host, David Williams, is joined by Pete O’Heeron, CEO of Fibrobiologics, explores the untapped potential of fibroblasts and their promise as a potentially superior and more affordable alternative to traditional stem-cell treatments. 🎙️⚕️ABOUT CARETALK CareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (President U.S. Healthcare and EVP, Walgreens Boots Alliance) and David Williams (President, Health Business Group) as they debate the latest in US healthcare news, business and policy. 🎙️⚕️ABOUT PETE O'HEERON Pete O'Heeron, an esteemed biopharma inventor, boasts over 300 patents in biologics, cell therapy, and medical devices. With 25+ years of expertise, he leads FibroBiologics as CEO, driving its emergence as a global leader in fibroblast-based cell ther
In this episode of "Conversations Life Science Leaders Aren't Having," we're joined by Pete O’Heeron, a notable figure in the life sciences sector, who leads groundbreaking advancements in cell therapy, focusing on fibroblasts at Fibrobiologics. Pete discusses his company's innovative work, highlighting the potential of fibroblasts over stem cells in tissue regeneration and the treatment of chronic diseases. He sheds light on the relative obscurity of fibroblasts compared to the widely known stem cells, despite fibroblasts significantly outnumbering them in the human body. This revelation presents a promising avenue for medical research and therapies. Pete then shares his journey in the life sciences and his current role since March 2021 at Fibrobiologics. Pete's dedication and the innovative approach of his team have positioned Fibrobiologics as a leader in exploring uncharted territories in biologics, significantly impacting the way chronic diseases are approached and treated. Thro
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Please Support The Channel by clicking here: ▀▀▀▀▀▀▀▀▀▀▀▀▀▀ Buy Me A Coffee: https://bit.ly/3Lw7YvI Support us on Patreon: https://bit.ly/3BmEInH ▀▀▀▀▀▀▀▀▀▀▀▀▀▀ Episode also available on Apple Podcasts: apple.co/30PvU9C Checkout FGP Website: https://www.findinggeniuspodcast.com/ SUBSCRIBE & REVIEW our Podcast on iTunes: https://apple.co/2L6tN88 Follow us on: Facebook: https://web.facebook.com/futuretechpodcast/ Twitter: https://twitter.com/finding_genius Instagram: https://www.instagram.com/findinggeniuspodcast/ LinkedIn: https://www.linkedin.com/company/finding-genius-podcast/ Timestamps: 0:00 Ad Introduction 0:50 FGP Introduction 2:57 Guest introduction 4:00 What is Fibroblast 5:51 Inject the cells 10:45 Other applications 13:10 Where these Fibroblast come 25:29 Find out about guest In this episode, we connect with Hamid Khoja, the Chief Scientific Officer of FibroBiologics. With experience as a researcher in the pharmaceutical industry, Hamid now works with FibroBiolog
FibroBiologics Chairman, CEO, & Founder Pete O'Heeron shares the journey that led him from clinical care to biopharma entrepreneurship, and he's joined by Chief Scientific Officer Hamid Khoja, Ph.D., who explains the manufacturing technology that's driving the company's exploitation of fibroblasts to develop regenerative therapies for indications ranging from degenerative disk disease and multiple sclerosis to cancer immunotherapies and therapeutics. #businessofbiotech #biopharma #biotech #cytiva http://cytiva.com/emergingbiotech Audio version available here: https://www.bioprocessonline.com/doc/fibroblasts-in-regenerative-medicine-with-fibrobiologics-pete-o-heeron-dr-hamid-khoja-0001 Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast/business-of-biotech/id1508008606?uo=4 Spotify - https://open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA Google - https://podcasts.google.com/?q=business%20of%20biotech
Dr. Hamid Khoja, Chief Scientific Officer at FibroBiologics, a regenerative medicine company developing treatment for chronic diseases using fibroblasts, talks about what fibroblasts are and how it could replace stem cell technology. The company’s indication of focus is multiple sclerosis and their fibroblast technology has demonstrated the ability to remyelinate nerve cells in pre-clinical studies. Small human efficacy studies have thus far demonstrated that treatment with fibroblasts helps improve the cognition and finger dexterity of MS patients. #FibroBiologics Dr. Hamid Khoja, Chief Scientific Officer, earned his Ph.D. in Molecular Biology at Boston University. He achieved the Dean’s List at Stanford University and received a Bachelor of Science from University of Southern California. He has a combined experience of 26 years developing genomic, proteomics, and epigenetics assays, tools, and protocols, for use in drug discovery/development, and clinical diagnostics.
“What we’ve seen in our limited clinical trial is that these tolerogenic fibroblasts, or CybroCell, we don’t see any side effects, or we haven’t seen any side effects.” The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology for this patient population, particularly the absence of adverse effects. For the original story, visit: (https://www.neurologylive.com/view/takeaways-clinician-cyms101-multiple-sclerosis-hamid-khoja)
Fibroblasts have demonstrated potent immune modulatory and therapeutic activity in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, as well as in other models of autoimmune and inflammatory diseases. This study will assess primary safety and secondary efficacy endpoints of intravenous administration of 100 million tolerogenic fibroblasts to 5 patients with relapsing remitting MS resistant to interferon. While the safety of fibroblasts administered clinically is established, it is unknown whether these cells are effective in the treatment of multiple sclerosis (MS). Our hypothesis is that the tolerogenic fibroblasts will be well-tolerated and meet our primary objective. In addition, The investigators are optimistic that they will see signs of efficacy based on the following: Neurological assessment of the MS functional composite assessment which comprises of EDSS, the expanded EDSS (Rating Neurologic Impairment in Multiple Sclerosis, the Scripps neurological rating scale (NRS), paced auditory serial addition test (PASAT), the nine-hole peg test, and 25-foot walking time, short-form 36 (SF-36) quality of life questionnaire and gadolinium-enhanced MRI scans of the brain and cervical spinal cord.
FibroBiologics CEO Pete O’Heeron to Speak at A4LI's H-SPAN Summit on Longevity Science | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On FBLG Stock Enter your email to receive free breaking news alerts and insights related to FBLG. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donald Trump Stock Trades Election Fundraising Insider Trading … actions, check out Quiver Quantitative's insider trading dashboard. $FBLG Hedge Fund Activity We have seen 21 institutional investors add shares of $FBLG stock to their portfolio, and 35 decrease their positions in their most recent quarter. Here are some of the largest recent moves: LANDSCAPE CAPITAL MANAGEMENT, L.L.C. added 350,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $191,170 YORKVILLE ADVISORS GLOBAL, LP removed 334,316 shares (-39.6%) from their
Instagram Instagram Log In Sign Up Close Never miss a post from fibrobiologics Sign up for Instagram to stay in the loop. Sign up Log in fibrobiologics • Follow More options fibrobiologics 5w Excited to share that Pete O'Heeron, Chairman, Founder, and CEO of FibroBiologics, will be speaking at the H-Span Summit at Georgetown University in Washington, DC. Looking forward to a Day 1 presentation, June 29–July 1, hosted by @thea4li Tickets and full agenda: https://a4li.org/h-span-summit-dc/ #FibroBiologics #Biotech #Longevity #HealthcareInnovation #FutureOfMedicine Load more comments No comm
FibroBiologics CEO Pete O'Heeron to speak at A4LI H-SPAN Summit | FibroBiologics (Nasdaq: FBLG) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue
You need to enable JavaScript to run this app. Loading...
Fibrobiologics explores use of fibroblast platform for hantavirus | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape
FibroBiologics Inc. (Nasdaq: FBLG) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 128 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> LD Micro Weekend Special (OS Edition) (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historical Data Share Info Time and Sales Insi
Instagram Instagram Log In Sign Up Close Never miss a post from cgxpwire Sign up for Instagram to stay in the loop. Sign up Log in cgxpwire • Follow More options cgxpwire 8w 🧬🧪 Innovation in Cancer Therapy FibroBiologics is advancing thymus organoid therapy to enhance immune responses in cancer treatment. This novel approach could reshape how immune systems are leveraged in oncology. 👉 https://cgxpwire.com/biopharma/fibrobiologics-advances-thymus-organoid-cancer-therapy/ #Biotech #Oncology #Innovation #Research Load more comments No comments yet. Start the conversation. Like Comment Share S
FibroBiologics Inc. (Nasdaq: FBLG) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 128 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> LD Micro Weekend Special (OS Edition) (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historical Data Share Info Time and Sales Insi
⚛️ FibroBiologics: Pioneering a... - RedChip Companies, Inc. Facebook Вход Публикация RedChip Companies, Inc. RedChip Companies, Inc. Подтвержденный аккаунт 1 январь · Поделился/-ась с Доступно всем FibroBiologics : Pioneering a Scalable Cell Therapy Platform FibroBiologics ( Nasdaq : FBLG) is advancing fibroblast-based therapies targeting multi-billion-dollar markets in wound healing, neurodegeneration, and autoimmune disease. Backed by 270+ patents and near-term clinical catalysts, including a Phase 1/2 trial for diabetic foot ulcers launching in 2025, FibroBiologics offers investors early e
EP4245306A1 - Therapeutic use of fibroblasts for use in wound healing - Google Patents EP4245306A1 - Therapeutic use of fibroblasts for use in wound healing - Google Patents Therapeutic use of fibroblasts for use in wound healing Download PDF Info Publication number EP4245306A1 EP4245306A1 EP23162313.3A EP23162313A EP4245306A1 EP 4245306 A1 EP4245306 A1 EP 4245306A1 EP 23162313 A EP23162313 A EP 23162313A EP 4245306 A1 EP4245306 A1 EP 4245306A1 Authority EP European Patent Office Prior art keywords fibroblast cells wound fibroblasts composition Prior art date 2022-03-16 Legal status (The legal … s and makes no representation as to the accuracy of the status listed.) Pending Application number EP23162313.3A Other languages German ( de ) French ( fr ) Inventor Pete O'HEERON Hamid Khoja Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Fibrobiologics Inc Original Assignee Fibrobiologics Inc Priority date (The priority date is an assumption and i … sted.) 2022-03-16 Filing date 2023-03-16 Publication date 2023-09-20 2023-03-16 Application filed by Fibrobiologics Inc filed Critical Fibrobiologics Inc 2023-09-20 Publication of EP4245306A1 publication Critical patent/EP4245306A1/en Status Pending legal-status Critical Current Links Espacenet EPO GPI EP Register Global Dossier Discuss Images Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, … l physical form A61K9/0012 — Galenical forms characterised by the site of application A61K9/0014 — Skin, i.e. galenical aspects of topical compositions A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61L — METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, … ny suitable form, including at least as a spray, gel, suspension, by mechanical application, on a device, in a gel matrix, included within a synthetic or organic polymer matrix, as 3D-cultured cells, and/or 3D-printed matrix, including comprising one or more cell types in some embodiments. one or more additional agents such as one or more growth
Loading... FibroBiologics Issues 4.48M Shares at $0.335 Each in Direct Offering | Intellectia.AI menu Search AI Trading Bot Features Markets News Resources Pricing Get Started Home ETF News FibroBiologics Issues 4.48M Shares at $0.335 Each in Direct Offering FibroBiologics Issues 4.48M Shares at $0.335 Each in Direct Offering Written by Emily J. Thompson , Senior Investment Analyst Source: Newsfilter Updated: Nov 24 2025 0 mins FBLG -3.42 % Explore Agentic Trading Explore Agentic Trading Let AI Trade for You Source: Newsfilter Funding Scale : FibroBiologics has announced a registered direct of … ewsfilter New Patent Filing : FibroBiologics has filed a new provisional patent application aimed at developing oral fibroblast and fibroblast-derived therapeutics, which could transform the treatment landscape for chronic diseases by enabling targeted delivery through the gastrointestinal tract. Multilayer Delivery Architecture : The patent describes a multilayer delivery platform utilizing hydrogels, nanoparticles, and pH-sensitive coatings to ensure therapeutic agents main … ewsfilter New Patent Filing : FibroBiologics has filed a new provisional patent application aimed at developing oral fibroblast and fibroblast-derived therapeutics, which could transform the treatment landscape for chronic diseases by enabling targeted delivery through the gastrointestinal tract. Multilayer Delivery Architecture : The patent describes a multilayer delivery platform utilizing hydrogels, nanoparticles, and pH-sensitive coatings to ensure therapeutic agents main
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
News Archives - Page 2 of 6 - FibroBiologics Skip to content FibroBiologics to Provide Company Update at Upcoming Conferences HOUSTON, September 14, 2023/PRNewswire/ – FibroBiologics, a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today that Pete O’Heeron, Founder/Chief Executive Officer, and Hamid Khoja Ph.D., Chief Scientific Officer, will be giving company presentations at the upcoming Life Science Intelligence (LSI) Europe […] FibroBiologics Dedic
FibroBiologics to Present at the BIO International Convention 2024 :: FibroBiologics, Inc. (FBLG) Skip to main content Skip to section navigation Skip to footer Investor Relations Back to fibrobiologics.com Overview News & Events Press Releases IR Calendar Presentations Email Alerts Company Info Company Profile Executive Team Contacts FAQ Financial Info Financial Results Stock Data Quote and Chart Historical Data Analyst Coverage SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Back … edule a meeting at the BIO International Convention with FibroBiologics, please submit a meeting request through the BIO One-on-One Partnering™ platform. For more information, please visit FibroBiologics' website or email FibroBiologics at [email protected]. About FibroBiologics Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells a
FibroBiologics to Present at the BIO International Convention 2025 :: FibroBiologics, Inc. (FBLG) Skip to main content Skip to section navigation Skip to footer Investor Relations Back to fibrobiologics.com Overview News & Events Press Releases IR Calendar Presentations Email Alerts Company Info Company Profile Executive Team Contacts FAQ Financial Info Financial Results Stock Data Quote and Chart Historical Data Analyst Coverage SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Back
MeiraGTx Licenses ZipBio's GA Treatment Technology | Jennie Crabbe posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre … ’s Surgical Techniques Workshop helped them develop practical skills they could apply immediately in their research. ⤵️ This in-person workshop covers surgical procedures commonly used in: • Hormone and behavioral studies • Immune and endocrine system research • Renal function assessment • Long-term vascular access • Reproductive control strategies Save your spot: https://lnkd.in/eUvat_2D 1 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign i … l and collaborate with a partner recognized for delivering highly standardized, application-ready human iPSC-derived immune cells—supporting your work through precise media and cytokine selection, phenotype and functional optimization, and fit-for-purpose cell performance, complemented by scalable process know-how when needed. Thanks to all co-authors and financial support #RESIST Medizinische Hochschule Hannover Fraunhofer ITEM European Research Council (ERC) Berlin Institut … ng intermediate-scale bioreactors for next-generation macrophage production and application - Nature Protocols nature.com 176 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in RedChip Companies 7,619 followers 3mo Report this post ⚛️ FibroBiologics: Pioneering a Scalable Cell Therapy Platform FibroBiologics (Nasdaq: FBLG) is advancing fibroblast-based therapies targeting multi-billion-dollar markets in wound healing, neurodegeneration, and autoimmu
+1- 800- RED-CHIP (733-2447) Toggle navigation Discovering Tomorrow's Blue Chips Today™ HOME ABOUT US Client Referrals Overview Team The RedChip Way Why CEO's Hire RedChip Case Studies In the News Careers SERVICES Value Proposition Investor Relations Digital IR TV and Media Education Newsletter Go Public CEO Interviews STOCKS EVENTS NEWSLETTER PODCASTS REDCHIP REVIEW CONTACT LOGIN FibroBiologics Inc. (NASDAQ: FBLG) Stock Information | RedChip NASDAQ: FBLG FibroBiologics, Inc. $0.96 -0.0030 (-0.31% ) Receive News Alerts Market: NASDAQ Price --> $0.96 Day Change --> -0.31% Mark
Frank Pereira, Author at FibroBiologics - Page 4 of 8 Skip to content FibroBiologics Launches Public Funding Campaign with StartEngine.com HOUSTON, January 31, 2023/PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today launched an online funding campaign with StartEngine, a leading equity crowdfunding platform. Regulation Crowdfunding allows everyone to invest in securities issued by startup companies, regardless of their net worth or income level. The funding […] Founders Keepers Podcast: Pete
FibroBiologics CEO on Base to Base Biotech Podcast | FibroBiologics (Nasdaq: FBLG) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … Compliance GMP certification is the baseline. For ATMPs, specialised guidelines apply. Seek partners with successful inspections by EMA, FDA, or MHRA - it’s proof of operational maturity. 3️⃣ Advanced Technologies Single-use bioreactors, closed-system processing, AI-driven process monitoring - these innovations cut contamination risk, boost yield, and support flexible scaling. 4️⃣ Scalability & Flexibility A strong partner can transition you from early clinical batches to
The latest news from Fibrobiologics in Houston TX Skip to content The Science of Fibroblasts Media Events Dec 14, 2023 10:00 AM FibroBiologics Investor Day FibroBiologics hosted an Investor Day Webinar on December 14, 2023, at 10 AM EST to discuss the company’s vision, strategy and science behind its fibroblast-based cell therapy platform. Press Releases Read More Media January 30, 2024 Houston regenerative medicine company to IPO, move toward more human trials Innovation Map January 8, 2024 Fibroblast Revolution and Visionary Leadership - with Pete O’Heeron Conversations Life Science Le
Interview with FibroBiologics … - HealthBiz with David E. Williams - Apple Podcasts Search Home New Top Charts Search June 27, 2024 25 min Interview with FibroBiologics CEO Pete O’Heeron HealthBiz with David E. Williams Play Listen in to this informative episode with Pete O'Heeron, CEO of FibroBiologics, as we explore his journey from a small, innovative town to the forefront of healthcare innovation. Pete shares how his upbringing in a medically inclined family and a community rich with inventiveness influenced his career. Hear how Pete transitioned from pre-med to hospital admini … applications across various medical fields. Highlighting the influence of Nobel Prize winners like Jim Allison and Jennifer Doudna, Pete discusses the promising results seen in wound care, multiple sclerosis, degenerative diseases, and more. With plans for upcoming clinical trials and commercialization strategies, Pete shares his admiration for influential figures like Elon Musk and reflects on the unique approaches to leadership in the biotech industry. Don't miss this engag
Progress in Developing Fibrobl… - Rx for Biotech - Apple Podcasts Search Home New Top Charts Search May 2, 2023 18 min Progress in Developing Fibroblast Cell Therapies with FibroBiologics CEO, Pete O'Heeron Rx for Biotech Play FibroBiologics is the leading biotech company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. In this podcast episode, the Founder and CEO, Pete O'Heeron discusses the promise of fibroblast cell therapy to treat diseases such as multiple sclerosis, degenerative disk disease and more. Episode Webpage
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Uncategorized Archives - FibroBiologics Skip to content Founders Keepers Podcast: Pete O’Heeron – Regenerative medicine and treating chronic disease with FibroBiologics Podcast: Pete O’Heeron – Regenerative medicine and treating chronic disease with FibroBiologics Kicking off the first episode of Founders Keepers of 2023 is Pete O’Heeron – the Founder and CEO of FibroBiologics. FibroBiologics is a clinical-stage regenerative medicine company based in Houston, Texas, developing a pipeline of treatments for chronic diseases using fibroblast cells. They hold over 150
Empowered Patient Podcast: Administering Fibroblasts to Regenerate Tissue in Treatment of Degenerative Disc Disease and MS with Hamid Khoja FibroBiologics Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing Healthcare Protesting … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
Fibroblasts In Regenerative Medicine With FibroBiologics Pete OHeeron Dr Hamid Khoja Get the latest industry news and expert insights delivered straight to your inbox! sign me up Log In or Subscribe Design & Development Regulatory Manufacturing Supply Chain 3D Additive Contract Manufacturing Electronics Materials Molding Package Sterilization Testing Podcast Fibroblasts In Regenerative Medicine With FibroBiologics' Pete O'Heeron & Dr. Hamid Khoja Source: Bioprocess Online access the Podcast! Log In Subscribe to access the full podcast FREE! Get unlimited access to: Trend and Thought Leader
FibroBiologics Granted Extension by Nasdaq to Regain Compliance - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press R … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Granted Extension by Nasdaq to Regain Compliance February 23, 2026 | 4 min read Twitter LinkedIn Facebook Email Print HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Thera … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update November 2, 2025 | 7 min read Twitter LinkedIn Facebook Email Print Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating … al evaluating CYWC628 in diabetic foot ulcers (DFU) patients Preparing to submit Investigational New Drug applications for the treatment of psoriasis with CYPS317 and the treatment of multiple sclerosis with CYMS101 HOUSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic dis … options for hematopoietic cancers and age-related immune decline. Filed patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Published a leadership-authored article in the Opinion Pages presenting the scientific case for fibroblast cells' therapeutic advantages compared to stem cell therapies. Presented recent updates on fibroblast-based therapi … riasis with CYPS317, FibroBiologics’ fibroblast spheroid product candidate, and submit IND. Complete pre-clinical IND-enabling studies for the treatment of multiple sclerosis with CYMS101, FibroBiologics’ fibroblast spheroid product candidate, and submit IND. “This quarter brought our strategy into greater focus,” said Pete O’Heeron, Founder and
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Ther … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics May 18, 2026 | 5 min read Twitter LinkedIn Facebook Email Print HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ pate … blast-derived materials, today announced the filing of a new provisional patent application with the U.S. Patent and Trademark Office (USPTO) titled “Oral Fibroblasts and Fibroblast-Derived Therapeutics and Delivery Systems for Same” covering oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract. The provisional patent application describes an oral administration platform intended … before releasing therapeutic payloads in targeted regions of the intestine. The application describes potential oral administration modality across chronic gastrointestinal disorders including inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, gastritis, Crohn's disease, ulcerative colitis, and gastrointestinal cancers. Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics commented, "A successful oral fibroblast therape … ure," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "The application covers not only fibroblasts, but also fibroblast-derived materials, engineered variants, multilayer encapsulation approaches, and programmable release concepts intended to maintain viability and function through oral delivery. From a scientific perspective
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update February 25, 2026 | 7 min read Twitter LinkedIn Facebook Email Print Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026 Improved balanc … up to 10 sites across Australia. Filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to advance the clinical development of CYPS317 in patients with psoriasis. Raised a total of $7.2M through multiple direct offerings. Repaid all outstanding debt. Expanded the patent portfolio with the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) covering a proprietary fibroblast-derived therapy platfo … blast spheroid product candidate, in the first half of 2026. Multiple Sclerosis Submit an IND application with the FDA for the treatment of multiple sclerosis with FibroBiologics’ fibroblast spheroid product candidate, CYMS101, in the first half of 2026. Degenerative Disc Disease Amend the IND clearance with the FDA to replace single-cell fibroblasts with fibroblast-derived chondrocyte spheroids derived from the CYWC628 master cell bank by the end of 2026. Pete O’Heeron, CEO … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Announces Closing of $3 Million Public Offering - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Re … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Announces Closing of $3 Million Public Offering April 3, 2026 | 4 min read Twitter LinkedIn Facebook Email Print HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Compliant with All Nasdaq Listing Requirements - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Compliant with All Nasdaq Listing Requirements April 21, 2026 | 3 min read Twitter LinkedIn Facebook Email Print HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending wi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Fibrobiologics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events J … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Fibrobiologics NEWS JOBS IN THE PRESS Press Releases FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers June 3, 2026 · 5 min read Press Releases FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psori … , 2026 · 5 min read Press Releases FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics May 18, 2026 · 5 min read Press Releases FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus May 11, 2026 · 6 min read Press Releases FibroBiologics CEO Issues Letter to Shareholders - May 5, 2026 May 5, 2026 · 6 min read Press Releases FibroBiologics Reports … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement March 26, 2026 | 3 min read Twitter LinkedIn Facebook Email Print Reverse Split Expected to Take Effect March 30, 2026 HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“Fib … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers June 3, 2026 | 5 min read Twitter LinkedIn Facebook Email Print HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinic … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer O … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update May 1, 2026 | 7 min read Twitter LinkedIn Facebook Email Print On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Fi … st spheroid product candidate, in the third quarter of 2026. Multiple Sclerosis Submit an IND application with the FDA for the treatment of multiple sclerosis with FibroBiologics’ fibroblast spheroid product candidate, CYMS101, in the second half of 2026. Degenerative Disc Disease Amend the IND clearance with the FDA to replace single-cell fibroblasts with fibroblast-derived chondrocyte spheroids derived from the CYWC628 master cell bank by the end of 2026. Pete O’Heeron, CEO … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics to Present at the DealFlow Discovery Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Re … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics to Present at the DealFlow Discovery Conference January 20, 2026 | 1 min read Twitter LinkedIn Facebook Email Print HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference January 6, 2026 | 1 min read Twitter LinkedIn Facebook Email Print HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-sta … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics to Present at the BIO Investment & Growth Summit 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics to Present at the BIO Investment & Growth Summit 2026 February 26, 2026 | 1 min read Twitter LinkedIn Facebook Email Print HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued a … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics to Present at Bio-Europe 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News &a … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics to Present at Bio-Europe 2025 October 27, 2025 | 1 min read Twitter LinkedIn Facebook Email Print HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on th … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busines … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis March 2, 2026 | 5 min read Twitter LinkedIn Facebook Email Print HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 July 7, 2025 | 4 min read Twitter LinkedIn Facebook Email Print HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ p … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells’ Therapeutic Advantages Over Traditional Stem Cell Therapies September 15, 2025 | 4 min read Twitter LinkedIn Facebook Email Print HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiolog … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean April 11, 2025 | 1 min read Twitter LinkedIn Facebook Email Print HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issue … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Presents at the ThymUS 2025 Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All N … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Presents at the ThymUS 2025 Meeting April 30, 2025 | 4 min read Twitter LinkedIn Facebook Email Print HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair April 3, 2025 | 4 min read Twitter LinkedIn Facebook Email Print HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 24 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Ther … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates February 5, 2025 | 1 min read Twitter LinkedIn Facebook Email Print FibroBiologics to also present at the BIO CEO & Investor Conference HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FB … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology March 12, 2026 | 5 min read Twitter LinkedIn Facebook Email Print HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cance … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting March 24, 2025 | 2 min read Twitter LinkedIn Facebook Email Print HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents i … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics Appoints Hamid Khoja, Ph.D. as Chief Scientific Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business FibroBiologics Appoints Hamid Khoja, Ph.D. as Chief Scientific Officer August 12, 2021 | 2 min read Twitter LinkedIn Facebook Email Print FibroBiologics, a clinical stage company developing fibroblast-based therapeutic solutions for chronic diseases, today announced the appointment of Hamid K … aris where he served as Principal Scientist responsible for long-term strategic application and technology development for their unique proprietary technology. Prior to Covaris, Dr. Khoja was a scientist at Genomic Solutions, Eli Lilly and Chiron Pharmaceuticals. Dr. Khoja graduated Magna Cum Laude with a Bachelor of Science in Molecular Biology from the University of Southern California and a Ph.D. in Molecular Biology from Boston University . About FibroBiologics Base … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FibroBiologics, Inc: FBLG Stock Price Quote & News | Robinhood Log In Sign Up Learn Blog Careers Help Log In Sign Up FibroBiologics, Inc 1D 1W 1M 3M YTD 1Y 5Y ALL Why Robinhood? Robinhood gives you the tools you need to put your money in motion. You can buy or sell FBLG and other ETFs, options, and stocks. Sign up About FBLG FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. Show more CEO Peter O'Heeron CEO Peter O' … uy or sell FBLG stocks, ETFs, and their options commission-free. Other fees may apply. See Robinhood Financial's fee schedule to learn more. Sign Up to Buy Watch FBLG
FibroBiologics CEO Issues Letter to Shareholders --> Accessibility: Skip TopNav Consumer Products and Services News Automobiles and Parts News Food & Beverage News Home Goods & Construction News Leisure Goods News Media & Entertainment News Personal Care News Retail News Travel and Leisure News Energy News Alternative Energy News Oil Gas and Coal News Chemicals News Banks & Financial Services News Banking News Closed-End Investments News Finance and Credit Services News Investment Banking and Brokerage Services News Insurance News Real Estate & REITs News Healthcare News He
Fibroblast cell-based therapies for chronic diseases | Fibrobiologics Skip to content Slide 1 What if the most common cell in the body could treat or cure some of the most common chronic diseases? Learn More Slide 2 Scientist Only Learn More Slide 3 Fibroblasts are a Practical and Economical Alternative to Stem Cells for Cell Therapy Learn More About Us Technology Pipeline Investor Relations News/Events Publications harnessing the power of fibroblasts What are Fibroblasts? There are only two cell types in the human body that can regenerate tissue and organs: stem cells and fibroblasts. Fibrobl
Fibrobiologics walks the unconventional financing path | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-ene … Download transcript Download episode Two CEOs discuss bracing for tariffs, NIH grant cuts and gifting China biopharma leadership position Play Listen Duration: 31:12 04-22-2025 As pharma deals with the impact of NIH grant cuts and what could follow with the imposition of tariffs, Robert Williamson, CEO of Triumvira Immunologics Inc., and Hernan Bazan, CEO of South Rampart Pharma LLC, brought their extensive experience in the industry to the podcast. Their concerns include ho
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University :: FibroBiologics, Inc. (FBLG) Skip to main content Skip to section navigation Skip to footer Investor Relations Back to fibrobiologics.com Overview News & Events Press Releases IR Calendar Presentations Email Alerts Company Info Company Profile Executive Team Contacts FAQ Financial Info Financial Results Stock Data Quote and Chart Historical Data Analyst Coverage SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Di
A fibroblast biopharmaceutical company targeting chronic diseases Skip to content Pioneering Experts Who We Are FibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. Our proprietary fibroblast platform serves as the foundation for developing biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involu … sed therapies. How We Came to Be ... After Shinya Yamanaka, Ph.D. won the Nobel Prize in 2012 for his work with induced pluripotent stem cells, the discovery race for stem cell advancement spread around the world. As break-throughs in the lab led to first-in-human trials for stem cells, our Founder, Pete O’Heeron recognized the potential therapeutic benefits of fibroblasts and began to develop the science around this “new” cell source. Fibroblasts, one of the most abundant ce
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Pete O'Heeron - FibroBiologics Skip to content Pete O'Heeron Chairman/Founder/CEO Pete O’Heeron is one of the most preeminent biopharma inventors of his generation, with over 350+ patents issued and pending in the areas of biologics, cell therapy and medical devices. Mr. O’Heeron is Chief Executive Officer of FibroBiologics and a seasoned leader in his field comprising over 25 years of experience in medical technology and biotech development. As CEO, he has positioned FibroBiologics to become a global leader in fibroblast-based cell therapies with the development and commercializati
Dr. Hamid Khoja, Chief Scientific Officer of FibroBiologics (Nasdaq: FBLG), explores potential innovative fibroblast-mediated therapies as non-surgical treatments for degenerative disc disease. Watch Dr. Hamid discuss FibroBiologics’ novel approach that could leverage the unique properties of fibroblasts to not only repair but also possibly replace damaged cartilage tissue in the spine. For more about our science, please visit https://bit.ly/3JzHquz #DegenerativeDiscDisease #CellTherapy #Innovation | FibroBiologics
FibroBiologics CSO on biotech, cell therapy, and AI | FibroBiologics (Nasdaq: FBLG) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
FibroBiologics CSO receives 61,607 stock options | FBLG Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oi … Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share . All 61,607 options are held directly and vest over four years, with one quarter vesting after one year and the remainder vesting monthly thereafter, contingent on continuous service. Positive None. Negative None. Insider Trade Summary 1 transaction reported Mixed 1 txn Insider Khoja Hamid Role Chief Scientific O … ider Khoja Hamid Role Chief Scientific Officer Type Security Shares Price Value Grant/Award Stock Option (Right to Buy) 61,607 $0.00 -- Holdings After Transaction: Stock Option (Right to Buy) — 61,607 shares (Direct, null) Footnotes (1) [object Object] Key Figures Options granted: 61,607 options Exercise price: $1.38 per share Post-grant option holdings: 61,607 options +3 more 6 metrics Options granted 61,607 options Stock Option (Right to Buy) grant on May 4, 2026 Exer … per share Conversion or exercise price for common stock underlying options Post-grant option holdings 61,607 options Total derivative securities following the grant, held directly Expiration date May 4, 2036 Option expiration for the granted stock options Initial vesting 25% after 1 year One fourth of option shares vest on first anniversary of grant date Remaining vesting period 36 monthly installments Balance vests monthly after first year, contingent on continuous service K … vesting financial "option shares shall vest on the one-year anniversary of the grant date" Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed
Press Releases :: FibroBiologics, Inc. (FBLG) Skip to main content Skip to section navigation Skip to footer Investor Relations Back to fibrobiologics.com Overview News & Events Press Releases IR Calendar Presentations Email Alerts Company Info Company Profile Executive Team Contacts FAQ Financial Info Financial Results Stock Data Quote and Chart Historical Data Analyst Coverage SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Back to fibrobiologics.com Press Releases News & Even
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa :: FibroBiologics, Inc. (FBLG) Skip to main content Skip to section navigation Skip to footer Investor Relations Back to fibrobiologics.com Overview News & Events Press Releases IR Calendar Presentations Email Alerts Company Info Company Profile Executive Team Contacts FAQ Financial Info Financial Results Stock Data Quote and Chart Historical Data Analyst Coverage SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Ba
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair :: FibroBiologics, Inc. (FBLG) Skip to main content Skip to section navigation Skip to footer Investor Relations Back to fibrobiologics.com Overview News & Events Press Releases IR Calendar Presentations Email Alerts Company Info Company Profile Executive Team Contacts FAQ Financial Info Financial Results Stock Data Quote and Chart Historical Data Analyst Coverage SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committee
Fibroblasts In Regenerative Me… - Business Of Biotech - Apple Podcasts Search Home New Top Charts Search June 20, 2022 56 min Fibroblasts In Regenerative Medicine with FibroBiologics' Pete O'Heeron & Dr. Hamid Khoja Business Of Biotech Play We love to hear from our listeners. Send us a message. FibroBiologics Chairman, CEO, & Founder Pete O'Heeron shares the journey that led him from clinical care to biopharma entrepreneurship, and he's joined by Chief Scientific Officer Hamid Khoja, Ph.D., who explains the manufacturing technology that's driving the company's exploitation of fibroblas
FibroBiologics Appoints Hamid Khoja, Ph.D. as Chief Scientific Officer :: FibroBiologics, Inc. (FBLG) Skip to main content Skip to section navigation Skip to footer Investor Relations Back to fibrobiologics.com Overview News & Events Press Releases IR Calendar Presentations Email Alerts Company Info Company Profile Executive Team Contacts FAQ Financial Info Financial Results Stock Data Quote and Chart Historical Data Analyst Coverage SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents B … aris where he served as Principal Scientist responsible for long-term strategic application and technology development for their unique proprietary technology. Prior to Covaris, Dr. Khoja was a scientist at Genomic Solutions, Eli Lilly and Chiron Pharmaceuticals. Dr. Khoja graduated Magna Cum Laude with a Bachelor of Science in Molecular Biology from the University of Southern California and a Ph.D. in Molecular Biology from Boston University. About FibroBiologics Based in Ho
Hamid Khoja, Ph.D. - Nasdaq Bell Ringing Ceremony | FibroBiologics (Nasdaq: FBLG) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User
Hamid Khoja - FibroBiologics Skip to content Hamid Khoja, Ph.D. Chief Scientific Officer Hamid Khoja, Ph.D. joined FibroBiologics as Chief Scientific Officer in August 2021. He leads all research, development, and advancement for the pipeline of cell therapy candidates. He has more than 25 years of experience as a leader of scientific teams, development of cell-based genomic, proteomic, epigenetics assays, and tools, protocols, and technologies for use in drug discovery and development and clinical diagnostics. He has distinguished himself with six patents issued/pending and 27+ peer reviewed